Latest News
Psychiatrists John Krystal, MD, and Gerard Sanacora, MD, PhD spoke to The Washington Post about how SSRIs -- serotonin reuptake inhibitors -- can cause heat intolerance and how to stay safe on hot days.
- June 19, 2025Source: The New York Times
Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, spoke to The New York Times about the benefits and possible dangers associated with the use of ketamine to treat depression, suicidal ideation and chronic pain.
- May 29, 2025Source: American Journal of Psychiatry
Greg Rhee, PhD, FACE, associate professor adjunct in psychiatry, is senior author of a paper in American Journal of Psychiatry that observed increasing trends of suicidal thoughts and suicide attempts among U.S. high school students from 2007 to 2021.
- May 13, 2025Source: Nature Genetics
A genome-wide analyses in Nature Genetics identified 30 independent loci associated with obsessive–compulsive disorder, highlighting genetic overlap with other psychiatric disorders and implicating putative effector genes and cell types contributing to its etiology. Marco Galimberti, PhD, associate research scientist, is co-first author.
- April 24, 2025
A new clinical trial launched by scientists at Yale School of Medicine and University of California San Francisco may offer hope to people with Parkinson’s disease who suffer from depression.
- March 18, 2025Source: The New York Times
In a “taper,” patients encounter difficulties of two kinds: withdrawal, and the relapse of underlying conditions, explained Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, and director of the Yale Depression Research Program, in a story in The New York Times.
- February 21, 2025Source: JAMA Psychiatry
Researchers, including first author Samuel Wilkinson, MD, associate professor of psychiatry, and senior author Greg Rhee, PhD, associate professor adjunct in psychiatry, wrote in JAMA Psychiatry about the need to conduct clinical trials to prevent suicide.
- February 10, 2025
A new device acquired by Yale Interventional Psychiatry Service has dramatically reduced the amount of time patients have to sit while undergoing transcranial magnetic stimulation for major depressive disorder.
- January 15, 2025
Patients are now being recruited for a study to compare the effectiveness of IV ketamine and esketamine nasal spray (otherwise known as Spravato) for people who suffer from treatment-resistant depression.
- December 09, 2024Source: The New York Times
Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, spoke to The New York Times about some common questions and misconceptions about antidepressants. Sanacora is director of the Yale Depression Research Program.